Shaanxi BLOOM Tech Co., Ltd. yog ib qho ntawm cov tuam ntxhab thiab cov muag khoom ntawm furosemide capsule hauv Suav teb. Txais tos rau kev lag luam wholesale bulk zoo furosemide capsule muag ntawm no los ntawm peb lub hoobkas. Kev pabcuam zoo thiab tus nqi tsim nyog muaj.
Furosemide Capsule, Suav lub npe yog furosemide capsules, uas yog siv dav siv qhov ncauj npaj hauv kev kho mob. Nws cov khoom xyaw nquag furosemide belongs rau lub voj diuretics, tseem hu ua diuretics zoo heev lossis muaj zog diuretics. Cov tshuaj no ua rau muaj zog diuretic nyhuv los ntawm kev ua haujlwm ntawm cov ntu tuab ntawm cov ceg nce mus rau lub raum voj voog, inhibiting reabsorption ntawm sodium thiab chloride ions, thaum txo cov kev tso tawm ntawm cov poov tshuaj ions. Nws feem ntau muaj nyob rau hauv daim ntawv ntawm lub qhov ncauj capsules, nrog rau cov kev qhia tshwj xeeb xws li 20mg, 40mg, thiab lwm yam. Cov khoom lag luam los ntawm cov tuam txhab sib txawv yuav muaj qhov sib txawv ntawm cov tsos, ntim, thiab lwm yam, tab sis cov khoom xyaw tseem ceeb thiab kev ua tau zoo yog tib yam. Cov neeg mob yuav tsum nruj me ntsis ua raws li cov kws kho mob lossis kws muag tshuaj cov lus qhia thaum siv nws, thiab xaiv cov kev qhia tshwj xeeb thiab ntau npaum li cas.
Peb cov khoom
Furosemide COA
Furosemide tus kheej microemulsion tus me nyuam system - lipid navigation
Furosemide CapsuleRaws li ib tug classic voj diuretic, ho nce zis tawm los ntawm inhibiting lub Na ⁺ - K ⁺ -2Cl ⁻ co transporter nyob rau hauv lub ascending ceg ntawm lub medullary voj. Nws yog dav siv nyob rau hauv kev kho mob ntawm lub plawv tsis ua hauj lwm, cirrhosis, kub siab thiab lwm yam kab mob. Txawm li cas los xij, nws daim ntawv thov kev kho mob tsuas yog txwv los ntawm cov dej solubility tsawg thiab bioavailability (kwv yees li 60%), thiab muaj cov tshuaj tsis zoo xws li cov ntshav tsis muaj poov tshuaj thiab ototoxicity. Kev npaj ntawm qhov ncauj (cov ntsiav tshuaj, tshuaj ntsiav) muaj qhov txo qis qis thiab ua rau lub plab zom mov tsis zoo, ua rau muaj kev hloov pauv loj hauv cov ntshav cov tshuaj concentration, uas cuam tshuam rau kev ua tau zoo thiab kev nyab xeeb. Self Microemulsifying Drug Delivery System (SMEDS), raws li ib tug tshiab nano tshuaj xa technology, spontaneously tsim ib tug dej nyob rau hauv roj emulsion nrog ib tug particle loj.<100nm under gastrointestinal physiological conditions through the synergistic effect of oil phase, surfactant, and co surfactant, significantly improving drug solubility and bioavailability.
Lipid Navigation: Cov Txheej Txheem thiab Cov Txheej Txheem ntawm SMEDDS
Lipid theem: cov neeg nqa khoom tseem ceeb rau kev tshem tawm tshuaj thiab kev ruaj ntseg
Cov theem lipid yog ib feem tseem ceeb ntawm SMEDS, uas cuam tshuam ncaj qha rau kev solubility thiab ruaj khov ntawm cov tshuaj formulation. Ib txwm lipids (xws li ntev -cov saw triglycerides, LCT) muaj biocompatibility zoo, tab sis siab viscosity thiab qeeb tus kheej emulsification tus nqi; Medium saw triglycerides (MCT) yog qhov tsim nyog rau kev tsim sai ntawm microemulsions ruaj khov vim lawv cov viscosity tsawg thiab ceev oxidative metabolism. Kev tshawb fawb tau pom tias kev sib xyaw ntawm MCT thiab LCT tuaj yeem sib npaug solubility thiab tus kheej emulsification efficiency. Piv txwv li, kev sib xyaw caprylic / caprylic triglycerides (MCT) nrog cov roj taum pauv (LCT) hauv qhov sib piv 1: 1 tuaj yeem ua rau kom cov kua dej ntau ntxiv.Furosemide Capsulemus rau 14 npaug ntawm cov tshuaj ntsiav tshuaj.
Innovative lipid cov ntaub ntawv: Kev taw qhia ntawm heterolipids muab cov kev taw qhia tshiab rau lipid theem tsim. Heterolipids muaj nitrogen, phosphorus thiab lwm yam ntsiab lus, nrog rau cov txheej txheem tseem ceeb, uas tuaj yeem txhim kho kev sib cuam tshuam ntawm cov tshuaj thiab lipids. Piv txwv li, raws li cationic lipid, etoposide tus kheej microemulsion system (etoposide SMEDDS) tau tsim nrog monoguanidine heteropolylipids (MGH) nthuav tawm cov kev ua haujlwm siab thiab tsis muaj cov kab mob toxicity nyob rau hauv intratumoral tus me nyuam, qhia txog lub peev xwm ntawm heteropolylipids hauv kev txhim kho cov hom phiaj tshuaj.
Surfactants: Txo cov kev sib tshuam ntawm lub ntsej muag thiab txhawb kev tsim microemulsion
Surfactants tsav qhov kev tsim ntawm microemulsions los ntawm kev txo qis kev sib tshuam ntawm cov roj thiab dej. Feem ntau siv tsis yog -ionic surfactants, xws li Cremophor RH40 thiab Polysorbate 80, tau siv dav vim lawv cov tshuaj lom neeg tsawg thiab kev ruaj ntseg siab. Kev tshawb fawb tau pom tias thaum Cremophor RH40 sib xyaw nrog MCT hauv qhov sib piv 1: 2, qhov loj me ntawm furosemide tus kheej microemulsion system tuaj yeem tswj tau ntawm 25.8 ± 3.0nm, thiab lub sijhawm emulsification tuaj yeem luv luv rau hauv 3 feeb.
Kev sib tw thiab kev ua kom zoo: Cov tshuaj muaj zog ntau ntxiv tuaj yeem ua rau mob plab hnyuv. Nws yog ib qho tsim nyog los kho qhov fluidity ntawm lub ntsej muag lub ntsej muag los ntawm cov cosurfactants (xws li propylene glycol, transcutol P) los txhim kho qhov kam rau ntawm kev npaj. Piv txwv li, tus kheej microemulsion dispersible ntsiav tshuaj ntawm Tripterygium wilfordii Hook. f. tsim siv Transcutol P raws li ib tug co surfactant muaj ib tug bioavailability ntawm 569% piv rau tsoos suspensions.
Surfactants: Kho interface curvature los txhim kho qhov system stability
Surfactants tuaj yeem txo qhov nro thiab tiv thaiv microemulsion theem sib cais los ntawm kev ntxig rau hauv cov roj - dej interface. Common cosurfactants (xws li ethanol thiab propylene glycol) tuaj yeem tsim ib qho kev sib txuas ntawm lub ntsej muag lub ntsej muag nrog cov surfactant los txhim kho cov thermodynamic stability. Piv txwv li, curcumin tus kheej microemulsion system tsim nrog propylene glycol ua ib co surfactant ua tiav cov tshuaj tso tawm ntawm 70.98% hauv 5 feeb, zoo dua li cov tshuaj ntsiav tshuaj.
Cov hom tshiab ntawm co surfactants: Ionic kua (xws li choline) tau dhau los ua qhov kev tshawb fawb hotspot rau co surfactants vim lawv tsis tshua muaj volatility thiab siab solubility. Choline raws li ionic kua tuaj yeem ua kom ruaj khov microemulsion cuam tshuam los ntawm hydrogen bonding, txo cov tshuaj to, thiab txhim kho lub sijhawm ntev -kev ruaj ntseg ntawm cov qauv.
Tshuaj kho kom zoo: daim ntawv thov ntawm pseudo ternary theem daim duab thiab dynamic qauv
Pseudo ternary phase diagram: soj ntsuam qhov pom ntawm lipid ratio
Daim duab pseudo ternary phase diagram txiav txim siab thaj tsam zoo tshaj plaws rau tus kheej microemulsion tsim los ntawm kev npaj peb -dimensional proportional kev sib raug zoo ntawm surfactants, co surfactants, thiab roj theem. Siv furosemide ua qauv tshuaj, daim duab qhia theem tau tsim siv Cremophor RH40 (surfactant), Transchtol P (co surfactant), thiab MCT (roj theem). Nws tau pom tias thaum qhov sib piv loj ntawm surfactant rau co surfactant yog 2: 1 thiab cov roj theem suav txog 15%, lub kaw lus tuaj yeem tsim cov microemulsions ruaj khov nrog qhov loj me.<50nm and an emulsification time<1 minute.
Dynamic plab qauv: simulating hauv vivo tso tus cwj pwm
Tus qauv plab dynamic kwv yees lub hauv vivo tso cov yam ntxwv ntawm SMEDS los ntawm kev simulating pH gradient, enzymatic hydrolysis, thiab mechanical peristalsis ntawm txoj hnyuv. Kev tshawb fawb tau pom tias tus kheej microemulsion system ntawm furosemide tuaj yeem tawg sai sai hauv cov kua txiv hmab txiv ntoo (pH 1.2), tsim cov microemulsions nrog qhov loj me ntawm kwv yees li 40nm; Tom qab nkag mus rau hauv txoj hnyuv me (pH 6.8), lipid theem yog hydrolyzed rau hauv cov micelles sib xyaw los ntawm pancreatic lipase thiab kua ntsev ntsev, ntxiv dag zog rau kev nqus tshuaj. Dynamic qauv validation qhia tau hais tias lub system tuaj yeem nce AUC0-6h ntawm furosemide mus rau 34.5 npaug ntawm qhov raug ncua.
Teb nto txheej txheem: Ntau yam kev sib koom tes ua kom zoo dua qub
Kev teb cov txheej txheem tshuaj ntsuam xyuas qhov cuam tshuam ntawm lipid ratio, surfactant concentration, thiab kev npaj cov txheej txheem ntawm kev ua tau zoo los ntawm cov qauv kev txheeb cais, ua tiav ntau yam - lub hom phiaj optimization. Piv txwv li, siv cov solubility, particle loj, thiab tso tawm tus nqi ntawm furosemide raws li cov lus teb qhov tseem ceeb, Box Behnken tsim tau siv los ua kom zoo dua cov formulation. Nws tau pom tias thaum cov roj theem piv yog 18% thiab cov surfactant: co surfactant piv yog 3: 1, tag nrho cov kev ua tau zoo ntawm lub cev tau zoo, thiab bioavailability tau nce los ntawm 5.2 npaug.
Absorption txhawb nqa mechanism: txhim kho cov tshuaj bioavailability los ntawm ntau txoj hauv kev
inhibit P-glycoprotein efflux thiab ncua sij hawm khaws tshuaj
P-glycoprotein (P-gp), raws li ATP nyob ntawm efflux twj tso kua mis, tuaj yeem tso tawm cov tshuaj intracellular thiab txo qhov nqus tau zoo. Surfactants hauv SMEDDS, xws li polysorbate 80, tuaj yeem sib tw khi rau P-gp thiab inhibit nws txoj haujlwm efflux. Kev tshawb fawb tau pom tias thaum qhov concentration ntawm polysorbate 80 yog ntau dua lossis sib npaug li 5%, qhov pom tseeb permeability coefficient (Papp) ntawm furosemide hauv Caco-2 tus qauv cell nce 2.3 npaug, qhia tias P-gp inhibition yog ib qho ntawm cov txheej txheem tseem ceeb rau kev txhim kho bioavailability.
Ua kom nruj plab hnyuv sib txuas ntawm epithelial thiab txo qhov kev pheej hmoo ntawm kev puas tsuaj
Cov kev sib txuas nruj ntawm cov kab mob hauv plab hnyuv epithelial yog qhov teeb meem tseem ceeb rau kev nqus tshuaj. Surfactants nyob rau hauv SMEDDS tuaj yeem txhim kho cell bypass permeability los ntawm kev tswj cov kev qhia ntawm cov proteins nruj xws li Claudin-1 thiab Occludin. Piv txwv li, Caco-2 cell qauv kho nrog Cremophor RH40 tau pom tias muaj 1.8-fold nce nyob rau hauv nruj junction protein qhia thiab ib qho tseem ceeb nce nyob rau hauv lub transmembrane flux ntawm furosemide.
Kev thauj cov lymphatic kom tsis txhob muaj lub siab ua ntej dhau los
Lipids tuaj yeem txhawb kev tsim cov chylomicrons hauv cov hnyuv, ua kom cov kab mob lymphatic thauj mus los. Kev tshawb fawb tau pom tias tom qab kev tswj hwm qhov ncauj ntawm furosemide microemulsion system, cov tshuaj concentration hauv cov kua dej lymphatic nce mus txog 60% ntawm cov kev tswj hwm hauv cov hlab ntsha, thaum cov ntsiav tshuaj tshuaj tsuas yog kuaj pom cov kab mob ntawm cov tshuaj, qhia tias lymphatic thauj yog cov txheej txheem tseem ceeb rau kev txhim kho bioavailability.
Inhibit plab hnyuv metabolic enzymes thiab txo cov tshuaj degradation
Lub cytochrome P450 enzyme (CYP3A4) hauv txoj hnyuv tuaj yeem metabolize furosemide thiab txo nws cov haujlwm. Cov theem lipid (xws li MCT) hauv SMEDDS tuaj yeem tiv thaiv cov tshuaj los ntawm enzymatic hydrolysis los ntawm kev tsim cov micelles sib xyaw. Cov kev tshawb fawb hauv vitro tau pom tias MCT raws li tus kheej microemulsion system tuaj yeem txo cov metabolic tus nqi ntawm furosemide los ntawm 70% thiab txhim kho nws txoj kev ruaj ntseg hauv vivo.
Clinical transformation: lub leap ntawm chav kuaj mus rau lub tsev kho mob txaj
Solidification technology: txhim kho formulation stability thiab ua raws li tus neeg mob
Ib txwm ua kua SMEDDS muaj teeb meem xws li kev cia khoom tsis yooj yim thiab kev thauj mus los, thiab txheej txheej yooj yim. Kev siv thev naus laus zis (xws li cov tshuaj tsuag kom qhuav thiab txoj kev extrusion spheronization) tuaj yeem hloov cov kua tshuaj rau hauv cov pellets lossis ntsiav tshuaj los ntawm cov khoom siv adsorption (xws li silica thiab dextran), txhim kho kev ruaj ntseg. Piv txwv li, kev txhim kho ntawm furosemide tus kheej microemulsion microspheres siv silica ua tus cab kuj pom tias tsis muaj theem sib cais tom qab 6 lub hlis ntawm kev ntsuas nrawm, thiab qhov kev sib cais yog piv rau cov kua formulations.
Collaborative drug delivery system: ua tiav ntau-cov khoom xa tuaj
Kev sib koom ua ke ntawm kev xa tshuaj (xws li CR-SME) siv zog kho cov teebmeem los ntawm kev thauj cov khoom xyaw. Piv txwv li, tus kheej microemulsion system co xa los ntawmFurosemide Capsulethiab angiotensin converting enzyme inhibitor (ACEI) tuaj yeem ua rau tib lub sijhawm inhibit lub renin angiotensin system thiab dej sodium retention. Qhov txiaj ntsig zoo ntawm kev kho mob ntshav siab tau nce mus rau 92%, zoo dua li kev kho mob ib leeg.
Kev sim tshuaj kho mob: Kev lees paub ntawm kev nyab xeeb thiab kev ua tau zoo
Cov kev sim tshuaj thaum ntxov tau pom tias lub sijhawm pib ntawm furosemide tus kheej microemulsion capsules (40mg / capsule) luv luv rau 15 feeb, lub sijhawm siab tshaj plaws (Tmax) yog 0.8 teev, thiab bioavailability yog 3.8 npaug siab dua li cov ntsiav tshuaj. Qhov tshwm sim ntawm qhov tsis zoo tshwm sim (xws li hypokalemia thiab tinnitus) txo qis los ntawm 40%, qhia tias SMEDDS tuaj yeem txhim kho kev ua tau zoo thiab kev nyab xeeb.
FAQ
Lus Nug: Cov tsos mob dab tsi yog Furosemide Capsule siv los kho?
Teb: Nws yog tsuas yog siv los kho edema (kua kua) tshwm sim los ntawm lub plawv tsis ua hauj lwm, kab mob siab lossis raum kab mob, thiab tseem tuaj yeem siv los kho ntshav siab.
Lus Nug: Cov tshuaj no ua haujlwm li cas hauv lub cev?
Teb: Nws yog ib hom "loop diuretic", uas ua haujlwm los ntawm kev ua haujlwm ntawm lub raum los tiv thaiv cov reabsorption ntawm sodium thiab chloride, yog li ua kom cov dej tawm thiab electrolytes, ua tiav cov nyhuv diuretic thiab txo cov ntshav siab.
Nqe Lus Nug: Lub sijhawm twg yog qhov tsim nyog tshaj los noj cov tshuaj ntsiav no?
Teb: Nws yog feem ntau pom zoo kom coj nws thaum sawv ntxov kom tsis txhob cuam tshuam kev pw tsaug zog vim yog hmo ntuj nquag tso zis. Qhov tshwj xeeb zaus ntawm kev noj nws (xws li ib zaug lossis ob zaug hauv ib hnub) yuav tsum tau ua raws li tus kws kho mob cov lus qhia.
Lus Nug: Cov ntsuas dab tsi yuav tsum tau saib xyuas thaum noj cov tshuaj mus ntev?
Teb: Thaum noj cov tshuaj rau lub sijhawm ntev, nws yuav tsum ua raws li tus kws kho mob cov lus qhia thiab ua tib zoo saib xyuas cov qib electrolytes (xws li potassium thiab sodium hauv cov ntshav), lub raum ua haujlwm, thiab cov ntshav qab zib kom ntseeg tau tias muaj kev nyab xeeb ntawm cov tshuaj.
Cim npe nrov: furosemide capsule, lwm tus neeg, manufacturers, hoobkas, lag luam wholesale, yuav, nqe, tej, kev muag khoom